Recent leadership turnover at the FDA, including Marty Makary's May 2026 resignation and Kyle Diamantas's appointment as acting commissioner, has left the permanent role open amid ongoing White House review of candidates. Trader consensus across multiple low-probability outcomes reflects uncertainty over timing, Senate confirmation hurdles, and competing priorities in an election year. Key differentiators among contenders include prior regulatory experience, alignment with administration health policy goals, and ability to manage agency culture and industry relations. Factors that could consolidate support include a formal nomination announcement, vetting completion, or shifts in legislative calendar that accelerate or delay the process before year-end.